Literature DB >> 15240627

Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes.

Deirdre G O'Donovan1, Selena Doran, Christine Feinle-Bisset, Karen L Jones, James H Meyer, Judith M Wishart, Howard A Morris, Michael Horowitz.   

Abstract

The determinants of postprandial blood glycemia are controversial. We assessed the effects of variations in the initial rate of small intestinal glucose delivery on blood glucose, plasma insulin, and incretin responses in both health and type 2 diabetes. Eight controls and eight patients with type 2 diabetes managed by diet alone underwent paired studies. On both days subjects received an intraduodenal glucose infusion (t = 0-120 min); on one day the infusion rate was variable, being more rapid initially (3 kcal/min) between t = 0 and 15 min and slower (0.71 kcal/min) subsequently (t = 15-120 min), whereas on the other day, the infusion rate was constant (1 kcal/min) from t = 0 to 120 min (i.e. on both days 120 kcal of glucose were administered). Between t = 0-180 min blood glucose, plasma insulin and plasma glucose-dependent insulin-releasing polypeptide were greater with the variable, compared with the constant, infusion. Between t = 0 and 30 min the magnitude of the rise in plasma glucagon-like peptide-1 was greater with the variable, compared with the constant infusion (P < 0.01, both groups). We conclude that modest variations in the initial rate of duodenal glucose entry may have profound effects on subsequent glycemic, insulin, and incretin responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240627     DOI: 10.1210/jc.2004-0334

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Effects of posture on gastric emptying, transpyloric flow, and hunger after a glucose drink in healthy humans.

Authors:  Karen L Jones; Deirdre O'Donovan; Michael Horowitz; Antonietta Russo; Yong Lei; Trygve Hausken
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

2.  To be or not to be--an incretin or enterogastrone?

Authors:  M Horowitz; M A Nauck
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

Review 3.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

4.  Alterations of Gastric Emptying Features Following Laparoscopic Sleeve Gastrectomy in Chinese Patients with Obesity: a Self-Controlled Observational Study.

Authors:  Mengyi Li; Yang Liu; Lan Jin; Wei Wang; Na Zeng; Lixue Wang; Kaixin Zhao; Wei Xu; Zhongtao Zhang; Jigang Yang
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

Review 5.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 6.  Gastric emptying and glycaemia in health and diabetes mellitus.

Authors:  Liza K Phillips; Adam M Deane; Karen L Jones; Chris K Rayner; Michael Horowitz
Journal:  Nat Rev Endocrinol       Date:  2014-11-25       Impact factor: 43.330

7.  Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Authors:  Jerry R Greenfield; I Sadaf Farooqi; Julia M Keogh; Elana Henning; Abdella M Habib; Anthea Blackwood; Frank Reimann; Jens J Holst; Fiona M Gribble
Journal:  Am J Clin Nutr       Date:  2008-12-03       Impact factor: 7.045

Review 8.  Diabetic gastroparesis: diagnosis and management.

Authors:  Jing Ma; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

9.  Impact of Sleeve Gastrectomy on Type 2 Diabetes Mellitus, Gastric Emptying Time, Glucagon-Like Peptide 1 (GLP-1), Ghrelin and Leptin in Non-morbidly Obese Subjects with BMI 30-35.0 kg/m2: a Prospective Study.

Authors:  B Vigneshwaran; Akshat Wahal; Sandeep Aggarwal; Pratyusha Priyadarshini; Hemanga Bhattacharjee; Rajesh Khadgawat; Rajkumar Yadav
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

10.  Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Authors:  Joan Khoo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.